Foresee Pharmaceuticals will present data from their Phase 3 KATANA studies evaluating FP-014, a novel triptorelin mesylate injection for advanced prostate cancer, at the 2025 ASCO-GU Symposium.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.